BiotechTube

DS3610a

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumors

Conditions

Solid Tumors, Metastatic Solid Tumors

Trial Timeline

Oct 9, 2025 → Feb 1, 2031

NCT ID
NCT07159126

About DS3610a

DS3610a is a phase 1 stage product being developed by Daiichi Sankyo for Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07159126. Target conditions include Solid Tumors, Metastatic Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07159126Phase 1Recruiting

Competing Products

20 competing products in Solid Tumors

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
25
BT1718Bicycle TherapeuticsPhase 1/2
33
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367Eli LillyPhase 1
33
BBP-398LianBioPhase 1
25

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85